风湿病患者肺结核进展的系统评价和荟萃分析

Q3 Medicine

Indian Journal of Tuberculosis Pub Date : 2025-04-01 DOI:10.1016/j.ijtb.2023.07.001

Karthikeyan Sundaram , Leela Kagithakara Vajravelu , Ravichandiran Velayutham , Utpal Mohan

{"title":"风湿病患者肺结核进展的系统评价和荟萃分析","authors":"Karthikeyan Sundaram , Leela Kagithakara Vajravelu , Ravichandiran Velayutham , Utpal Mohan","doi":"10.1016/j.ijtb.2023.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Tuberculosis is a contagious disease that ranks among the top ten killers of humans worldwide. <span><span>Mycobacterium tuberculosis</span></span> is an etiological agent of tuberculosis. The prognosis of tuberculosis in patients with autoimmune diseases is high due to treatment with <em>anti</em>-TNF-alpha therapy.</div></div><div><h3>Methods and materials</h3><div>We analyzed the studies based on the Preferred Reporting Items and Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Methods of eligibility criteria, search criteria and critical analyses, biased and challenges, and intervention.</div></div><div><h3>Results</h3><div><span><span>We observed the tuberculosis incidence of 595 (3.25%; 95% CI- 2.9 – 3.5) cases in systemic lupus erythematosus, 332 (4.54%; 95% CI - 4.07 - 5.01) in </span>rheumatoid arthritis, and 25 (1.9%; 95% CI - 1.16 – 2.64) in </span>multiple sclerosis out of 26,870 study populations in the various studies, and a total of 93 (7.2%; 95% CI - 5.8 – 8.6) cases in MS, and 10 (0.05%; 95% CI - 0.02 – 0.08) in SLE reported of TB indeterminate results.</div></div><div><h3>Conclusion</h3><div><span>This systematic review comprehensively analyzed the recent studies of the disease progression of latent </span>tuberculosis infection<span> to active tuberculosis is high in treatments with glucocorticoid<span><span>, azathioprine, </span>prednisone<span>, and leflunomide among patients with autoimmune diseases.</span></span></span></div></div><div><h3>Key findings</h3><div><span>We summarized recent studies emphasizing the risk factors of tuberculosis to be found the disease-modifying anti-rheumatic drug (DMARD), immunosuppressive treatments given to biologic-naive patients as the dominant factor associated with the risk of TB and treatment with a </span>tumor necrosis factor inhibitor.</div></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"72 2","pages":"Pages 174-182"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progression of tuberculosis among patients with rheumatic diseases – A systematic review and meta-analysis\",\"authors\":\"Karthikeyan Sundaram , Leela Kagithakara Vajravelu , Ravichandiran Velayutham , Utpal Mohan\",\"doi\":\"10.1016/j.ijtb.2023.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Tuberculosis is a contagious disease that ranks among the top ten killers of humans worldwide. <span><span>Mycobacterium tuberculosis</span></span> is an etiological agent of tuberculosis. The prognosis of tuberculosis in patients with autoimmune diseases is high due to treatment with <em>anti</em>-TNF-alpha therapy.</div></div><div><h3>Methods and materials</h3><div>We analyzed the studies based on the Preferred Reporting Items and Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Methods of eligibility criteria, search criteria and critical analyses, biased and challenges, and intervention.</div></div><div><h3>Results</h3><div><span><span>We observed the tuberculosis incidence of 595 (3.25%; 95% CI- 2.9 – 3.5) cases in systemic lupus erythematosus, 332 (4.54%; 95% CI - 4.07 - 5.01) in </span>rheumatoid arthritis, and 25 (1.9%; 95% CI - 1.16 – 2.64) in </span>multiple sclerosis out of 26,870 study populations in the various studies, and a total of 93 (7.2%; 95% CI - 5.8 – 8.6) cases in MS, and 10 (0.05%; 95% CI - 0.02 – 0.08) in SLE reported of TB indeterminate results.</div></div><div><h3>Conclusion</h3><div><span>This systematic review comprehensively analyzed the recent studies of the disease progression of latent </span>tuberculosis infection<span> to active tuberculosis is high in treatments with glucocorticoid<span><span>, azathioprine, </span>prednisone<span>, and leflunomide among patients with autoimmune diseases.</span></span></span></div></div><div><h3>Key findings</h3><div><span>We summarized recent studies emphasizing the risk factors of tuberculosis to be found the disease-modifying anti-rheumatic drug (DMARD), immunosuppressive treatments given to biologic-naive patients as the dominant factor associated with the risk of TB and treatment with a </span>tumor necrosis factor inhibitor.</div></div>\",\"PeriodicalId\":39346,\"journal\":{\"name\":\"Indian Journal of Tuberculosis\",\"volume\":\"72 2\",\"pages\":\"Pages 174-182\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Tuberculosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0019570723001294\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019570723001294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

结核病是一种传染性疾病，是全球十大人类杀手之一。结核分枝杆菌是结核的一种病原。由于抗tnf - α治疗，自身免疫性疾病患者的结核病预后高。方法和材料我们根据首选报告项目和系统评价和荟萃分析（PRISMA）指南对研究进行分析。方法的资格标准，搜索标准和关键分析，偏见和挑战，和干预。结果本院肺结核发病率595例(3.25%；系统性红斑狼疮332例（95% CI- 2.9 - 3.5）；95% CI - 4.07 - 5.01)， 25例(1.9%；在各种研究的26870个研究人群中，多发性硬化症的95% CI为1.16 - 2.64)，共有93例(7.2%；95% CI - 5.8 - 8.6)例多发性硬化症，10例(0.05%；95% CI - 0.02 - 0.08)在SLE中报告的结核结果不确定。结论本系统综述综合分析了近年来有关自身免疫性疾病患者应用糖皮质激素、硫唑嘌呤、强的松和来氟米特治疗后潜伏性结核感染向活动性结核发展的研究。主要发现我们总结了最近的研究，强调结核病的危险因素是发现疾病修饰抗风湿药物（DMARD），对生物初始患者给予免疫抑制治疗是与结核病风险相关的主要因素，以及肿瘤坏死因子抑制剂的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Progression of tuberculosis among patients with rheumatic diseases – A systematic review and meta-analysis

Background

Tuberculosis is a contagious disease that ranks among the top ten killers of humans worldwide. Mycobacterium tuberculosis is an etiological agent of tuberculosis. The prognosis of tuberculosis in patients with autoimmune diseases is high due to treatment with anti-TNF-alpha therapy.

Methods and materials

We analyzed the studies based on the Preferred Reporting Items and Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Methods of eligibility criteria, search criteria and critical analyses, biased and challenges, and intervention.

Results

We observed the tuberculosis incidence of 595 (3.25%; 95% CI- 2.9 – 3.5) cases in systemic lupus erythematosus, 332 (4.54%; 95% CI - 4.07 - 5.01) in rheumatoid arthritis, and 25 (1.9%; 95% CI - 1.16 – 2.64) in multiple sclerosis out of 26,870 study populations in the various studies, and a total of 93 (7.2%; 95% CI - 5.8 – 8.6) cases in MS, and 10 (0.05%; 95% CI - 0.02 – 0.08) in SLE reported of TB indeterminate results.

Conclusion

This systematic review comprehensively analyzed the recent studies of the disease progression of latent tuberculosis infection to active tuberculosis is high in treatments with glucocorticoid, azathioprine, prednisone, and leflunomide among patients with autoimmune diseases.

Key findings

We summarized recent studies emphasizing the risk factors of tuberculosis to be found the disease-modifying anti-rheumatic drug (DMARD), immunosuppressive treatments given to biologic-naive patients as the dominant factor associated with the risk of TB and treatment with a tumor necrosis factor inhibitor.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Tuberculosis Medicine-Infectious Diseases

CiteScore

2.80

自引率

0.00%

发文量

103

期刊介绍： Indian Journal of Tuberculosis (IJTB) is an international peer-reviewed journal devoted to the specialty of tuberculosis and lung diseases and is published quarterly. IJTB publishes research on clinical, epidemiological, public health and social aspects of tuberculosis. The journal accepts original research articles, viewpoints, review articles, success stories, interesting case series and case reports on patients suffering from pulmonary, extra-pulmonary tuberculosis as well as other respiratory diseases, Radiology Forum, Short Communications, Book Reviews, abstracts, letters to the editor, editorials on topics of current interest etc. The articles published in IJTB are a key source of information on research in tuberculosis. The journal is indexed in Medline